XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2024
Dec. 31, 2023
ASSETS    
Cash and cash equivalents $ 28,293 $ 22,593
Marketable securities 9,969 27,942
Prepaid and other current assets 3,716 3,389
Total current assets 41,978 53,924
Property and equipment, net 119 175
Acquired license - intangible, net 228 263
Other assets 246 332
Total assets 42,571 54,694
Liabilities    
Accounts payable 728 2,421
Accrued liabilities 3,729 4,169
Total current liabilities 4,457 6,590
Other long-term liabilities 119 210
Total liabilities 4,576 6,800
Commitments and Contingencies (Note 13)
Stockholders' Equity    
Common stock, $0.001 par value, authorized 500,000,000 shares; issued 8,321,799 and 8,150,635 shares at June 30, 2024 and December 31, 2023, respectively; and outstanding, 8,321,061 and 8,149,897 shares at June 30, 2024 and December 31, 2023, respectively 8 8
Additional paid-in capital 577,552 576,971
Treasury stock, at cost; 738 shares at June 30, 2024 and December 31, 2023 (708) (708)
Accumulated deficit (538,526) (528,081)
Accumulated other comprehensive loss (77) (42)
Total Lisata Therapeutics, Inc. stockholders' equity 38,249 48,148
Non-controlling interests (254) (254)
Total equity 37,995 47,894
Total liabilities, non-controlling interests and stockholders' equity $ 42,571 $ 54,694